Clay B. Siegall is a cancer researcher who has specialized in oncology/cancer. He is a scientist by training but with a passion and emphasis on targeted cancer therapies. He is also the co- founder of Seattle Genetics as well as the Chief Executive Officer and the Chairman of the Board. Dr. Clay built Seattle Genetic on a foundation of scientific innovation, arduous research and drug development practices as well as the passion to helping patients.
Clay Siegall says his motivation to starting a Biotechnology company was the loss of his father who was suffering from cancer when he was only 19 years old. Unavailability of treatment led to his father’s death; this made him dedicated to finding a cure for cancer and also give the available doctors new options to treat cancers.
His success and productivity in his business are due to the collaboration with other drug companies. The drug companies have helped him come up with new products, create them and reach new customers. This partnership allowed Seattle Genetics Company to make to make money off of licensing agreements with its original technology.
Clay studied zoology as an undergraduate in college. He obtained his Ph.D. and degree from George Washington University in doctoral dissertation and genetics. Before starting up his research and drug development center for cancer in 1998, Clay worked at the Bristol-Myers Squibb Pharmaceutical Research Institute of Health and also at National Cancer Institute from 1991 to 1997.
He used the experiences he gained in working in the research institute, and that is when he came up with his company, Seattle Genetics. At Seattle Genetics, Clay leads a group of employees to create a new cancer treatment. So far, he has helped come up with an antibody drug known as Adcetris which medically in a way destroys cancerous cells in the body.
Dr. Seigall has on several occasions been awarded for his various works over the years.